Figure 1
NDGA analogs Af23 and Ad23 inhibited FGFR1 activities in a non-ATP competitive manner. (A) The profile of design and FGFR1 kinase inhibition assay of NDGA analogs. FGFR1 kinase inhibition rates of the compounds were evaluated by caliper mobility shift assay, and IC50 values were calculated using conversion rates. The data were shown as a mean of 3–5 independent tests. (B) Af23 and Ad23 inhibit FGFR1 through a mechanism that is independent of the concentration of ATP. Selective ATP-competitive kinase assay of compounds Ad23 (B), Af23 (C), and NDGA (D) with FGFR1 was carried out through caliper mobility shift assay. The conversion data were fitted with Graphpad for global fitting, using “mixed model inhibition”.